ArticleJournal of gastroenterology2026
Clinical significance of gadoxetate sodium-enhanced MRI for detecting liver metastasis in patients with pancreatic cancer: decadal real-world data analysis in Japan.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrecise, early diagnosis of liver metastasis improves clinical outcomes in patients with pancreatic cancer. While gadoxetate sodium-enhanced magnetic resonance imaging (EOB-MRI) may offer additional benefits in detecting liver metastases in patients with pancreatic cancer, it is still unclear whether the addition of this imaging modality to contrast-enhanced computed tomography (CE-CT) confers clinical benefits regarding prognosis and access to appropriate treatments. The objective is to evaluate the treatment pathway of patients with or without EOB-MRI after a pancreatic cancer diagnosis and examine whether the addition of EOB-MRI is associated with improved survival.
methodsA retrospective cohort study was conducted using a Japanese hospital-based administrative database. Patients aged ≥ 18 years and diagnosed with pancreatic cancer between 2011 and 2021 with any record of CE-CT or MRI were included. Patients were stratified based on a record of EOB-MRI (EOB-MRI vs. non-EOB-MRI). Main outcomes were treatment pathway and overall survival (OS). OS was compared between the EOB-MRI and non-EOB-MRI groups using Cox proportional hazard regression models in the propensity-score-matched cohort.
resultsA total of 39,624 patients were included. The proportion of neoadjuvant chemotherapy increased to 13.4% during recent years (2019-2021) in the EOB-MRI group versus 7.8% in the non-EOB-MRI group. Significantly longer OS in the matched cohort was observed (HR [95% CI] = 0.88 [0.83-0.94]) in the EOB-MRI group (1,442 days [1275-1604]) versus the non-EOB-MRI group (1,293 days [1187-1440]).
conclusionsThe addition of EOB-MRI was associated with increased survival times in patients with pancreatic cancer.
Indexed as
Identifiers
42081098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.